Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Companyâ€™s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patientâ€™s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	1.38M 1.18M 1.11M 1.01M 1.91M 132M 1.93M 13.08M 5.09M 66.45M 5.19M 5.07M 220M	P/E 2024	-2.41x	P/E 2025	-3.27x
Enterprise Value	1.46M 1.25M 1.17M 1.07M 2.02M 139M 2.04M 13.84M 5.39M 70.29M 5.49M 5.37M 233M	EV / Sales 2024	497x	EV / Sales 2025	-
Free-Float	83.91%	Yield 2024 *	-	Yield 2025	-

08-14	Abpro Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Abpro Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Abpro Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Abpro Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-25	Abpro Holdings, Inc.(NasdaqCM:ABP) dropped from S&P TMI Index	CI
02-19	Abpro Holdings, Inc.(OTCPK:ABPO) dropped from NASDAQ Composite Index	CI
02-03	Abpro Holdings, Inc. Announces Board and Committee Resignations	CI
01-23	Abpro Holdings, Inc. Announces Board and Committee Changes	CI
01-16	Abpro Holdings, Inc. announced that it expects to receive $0.147 million in funding	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
12-15	Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers	RE
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI

01-15	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
01-06	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
12-15	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
12-09	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
11-04	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABPRO CORPORATION	-.--%	-.--%	-	-	1.38M
LONZA GROUP AG	-0.35%	+2.11%	+2.28%	+24.37%	51.65B
REVOLUTION MEDICINES, INC.	-0.09%	-2.14%	+492.60%	+537.84%	45.31B
IQVIA HOLDINGS INC.	-0.32%	+8.08%	+37.97%	+18.45%	42.7B
BEONE MEDICINES AG	+1.18%	+1.96%	+21.95%	+89.69%	42.79B
CELLTRION, INC.	-2.27%	-3.02%	+14.22%	+51.50%	32.87B
MEDPACE HOLDINGS, INC.	-0.96%	+4.03%	+31.55%	+136.34%	17.14B
ASCENDIS PHARMA A/S	+0.41%	+1.66%	-	-	16.61B
EUROFINS SCIENTIFIC SE	+0.32%	+5.12%	+13.34%	+31.14%	15.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.31%	+6.61%	+81.37%	+48.53%	14.21B
Average	-0.26%	+2.97%	+86.91%	+117.23%	30.92B
Weighted average by Cap.	-0.27%	+2.74%	+104.56%	+135.43%

	2024	2025
Net sales	183K 157K 147K 134K 253K 17.45M 256K 1.73M 675K 8.8M 687K 672K 29.15M	-
Net income	-7.23M -6.2M -5.81M -5.3M -10.01M -689M -10.11M -68.49M -26.66M -348M -27.15M -26.56M -1.15B	-2.89M -2.48M -2.32M -2.12M -4M -276M -4.04M -27.39M -10.66M -139M -10.86M -10.62M -461M
Net Debt	478K 410K 384K 351K 662K 45.57M 668K 4.53M 1.76M 22.99M 1.79M 1.76M 76.14M	80K 68.55K 64.23K 58.67K 111K 7.63M 112K 758K 295K 3.85M 300K 294K 12.74M

Abpro Corporation Share Price Nasdaq

Stocks

US0008501076

Biotechnology & Medical Research

Valuation: Abpro Corporation

Latest news : Abpro Corporation

Press Releases: Abpro Corporation

Other Biotechnology & Medical Research

Financials

Company Profile